Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PPM1B | O75688 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27714334 | 0.88 | SMN1; SMN2 (0.53) | TP53SMN1; SMN2PPM1BPTPN1PPP1CC | |
| SCHEMBL17802873 | 0.87 | TP53 (0.46) | TP53SMN1; SMN2PPM1BPTPN1PPP1CC | |
| SCHEMBL14146570 | 0.86 | — | — | |
| SCHEMBL1127208 | 0.86 | — | — | |
| SCHEMBL31368068 | 0.84 | TP53 (0.40) | TP53SMN1; SMN2PPM1BPTPN1PPP1CC | |
| SCHEMBL2948892 | 0.82 | TP53 (0.56) | TP53SMN1; SMN2PPM1BPTPN1PPP1CC | |
| SCHEMBL2200767 | 0.82 | TP53 (0.56) | TP53SMN1; SMN2PPM1BPTPN1PPP1CC | |
| SCHEMBL74396 | 0.82 | TP53 (0.56) | TP53SMN1; SMN2PPM1BPTPN1PPP1CC | |
| SCHEMBL244740 | 0.82 | — | — | |
| SCHEMBL2874292 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2CHRNB2CHRNA4CHRNA3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1985 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129094-A1 | NEW QUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-04-24 | — | — | US | claimed |
| US-20250075147-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS | OSMO LABS, PBC | 2025-03-06 | — | — | US | claimed |
| EP-4399209-A1 | NEW QUINOLINE DERIVATIVES | Elanco Animal Health GmbH (DE) | 2024-07-17 | — | — | EP | claimed |
| CN-117957223-A | Quinoline derivatives | 礼蓝动物保健有限公司 | 2024-04-30 | — | — | CN | claimed |
| WO-2023036821-A1 | NEW QUINOLINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2023-03-16 | — | — | WO | claimed |
| EP-4148052-A1 | NEW QUINOLINE DERIVATIVES | Bayer Animal Health GmbH (DE) | 2023-03-15 | — | — | EP | claimed |
| CN-113501828-B | 2,8-dioxaspiro [4.5] decane-1-ketone, and preparation method and application thereof | 上海毕得医药科技股份有限公司 | 2023-02-21 | — | — | CN | claimed |
| CN-113501828-A | 2, 8-dioxaspiro [4.5] decane-1-one and preparation method and application thereof | 上海毕得医药科技股份有限公司 | 2021-10-15 | — | — | CN | claimed |
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| WO-2026090509-A1 | SPIRO HETEROCYCLIC CDK2 INHIBITORS | ARCHITECT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12583836-B2 | Sulphonamide compounds | Anaxis Pharma Pty Ltd (AU) | 2026-03-24 | — | — | US | disclosed |
| US-12559481-B2 | Quinoline derivatives | ELANCO ANIMAL HEALTH GMBH (DE) | 2026-02-24 | — | — | US | disclosed |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| US-5532386-A | CATALYTIC CARBONIC ESTER AND A TERTIARY AMINE | BASF AKTIENGESELLSCHAFT (DE) | 1996-07-02 | — | — | US | disclosed |
| US-5412120-A | Catalytic decarboxylation of corresponding geminal dicarboxylic acid | BASF AKTIENGESELLSCHAFT (DE) | 1995-05-02 | — | — | US | disclosed |
| US-5371242-A | Catalytic hydrogenation of 4-hydroxybutyric acid to give tetrahydrofurans or diols | BASF AKTIENGESELLSCHAFT (DE) | 1994-12-06 | — | — | US | disclosed |
| US-5371246-A | Preparation of tetrahydropyran-4-carboxylic acid and esters thereof | BASF AKTIENGESELLSCHAFT (DE) | 1994-12-06 | — | — | US | disclosed |
| US-5252755-A | Reducing with hydrogen in the presence of hydrogenation catalysts | BASF AKTIENGESELLSCHAFT (DE) | 1993-10-12 | — | — | US | disclosed |
| US-4837346-A | REACTION OF 3-(2-HYDROXYETHYL)BUTYROLACTONE OR ESTERS AND ETHE RS THEREOF WITH ALCOHOLS IN THE PRESENCE OF AN ACID CATALYST | BASF AKTIENGESELLSCHAFT (DE) | 1989-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583836-B2 | Sulphonamide compounds | MLKL, RIPK3, CASP1 | TP53 2934/4885SMN1; SMN2 761/4885PPM1B 661/4885 |
| US-20250129094-A1 | NEW QUINOLINE DERIVATIVES | RECQL, QTRT2, NQO2 | TP53 2876/4885SMN1; SMN2 2653/4885PPM1B 3590/4885 |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | TP53 3140/4885SMN1; SMN2 4623/4885PPM1B 2679/4885 |
| US-12559481-B2 | Quinoline derivatives | HRH1, HRH2, HRH4 | TP53 4058/4885SMN1; SMN2 3529/4885PPM1B 3468/4885 |
| US-12545684-B2 | CDK2 inhibitors | CDK2, CDK4, CDK1 | TP53 207/4885SMN1; SMN2 2767/4885PPM1B 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.